References
- Cancer Genome Atlas Research N, Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. The N Engl J Med 2015; 372: 2481-98. doi: 10.1056/NEJMoa1402121
- Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, et al. Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. J Neurosurg 2009; 111: 20310. doi: 10.3171/2009.2.Jns081101
- Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 2008; 109: 817-24. doi: 10.3171/jns/2008/109/11/0817
- Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996; 36: 549-56. doi: 10.1016/s0360-3016(96)00352-5
- van den Bent MJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol 2014; 16: 1570-4. doi: 10.1093/neuonc/nou297
- Delfanti RL, Piccioni DE, Handwerker J, Bahrami N, Krishnan A, Karunamuni R, et al. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol 2017; 135: 601-9. doi: 10.1007/s11060-017-2613-7
- Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014; 16: 81-91. doi: 10.1093/neuonc/not159
- Villani V, Merola R, Vidiri A, Fabi A, Carosi M, Giannarelli D, et al. Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up. Tumori 2017; 103: 255-60. doi: 10.5301/tj.5000565
- Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307. doi: 10.1038/nature10144
- Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 2011; 28: 13-24. doi: 10.1007/s10014-010-0007-z
- Gaddikeri S, Gaddikeri RS, Tailor T, Anzai Y. Dynamic contrast-enhanced MR imaging in head and neck cancer: techniques and clinical applications. AJNR Am J Neuroradiol 2016; 37: 588-95. doi: 10.3174/ajnr.A4458
- Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: 891-9.
- Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D, et al. Glial neoplasms: Dynamic Contrast-enhanced T2*-weighted MR imaging. Neuroradiology 1999; 211: 791-8. doi: 10.1148/radiology.211.3.r99jn46791.
- Hino T, Togao O, Hiwatashi A, Yamashita K, Kikuchi K, Momosaka D, et al. Clinical efficacy of simplified intravoxel incoherent motion imaging using three b-values for differentiating high- and low-grade gliomas. PLoS One 2018; 13: e0209796-e. doi: 10.1371/journal.pone.0209796
- Wang X, Chen XZ, Shi L, Dai JP. Glioma grading and IDH1 mutational status: assessment by intravoxel incoherent motion MRI. Clin Radiol 2019; 74: 651. e7-651.e14. doi: 10.1016/j.crad.2019.03.020
- Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011; 196: 1351-61. doi: 10.2214/AJR.10.5515
- Awasthi R, Rathore RK, Soni P, Sahoo P, Awasthi A, Husain N, et al. Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers. Neuroradiology 2012; 54: 205-13. doi: 10.1007/s00234-011-0874-y
- Lu S, Gao Q, Yu J, Li Y, Cao P, Shi H, et al. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor. Eur J Radiol 2016; 85: 1722-7. doi: 10.1016/j.ejrad.2016.07.005
- Togao O, Hiwatashi A, Yamashita K, Kikuchi K, Mizoguchi M, Yoshimoto K, et al. Differentiation of high-grade and low-grade diffuse gliomas by intra-voxel incoherent motion MR imaging. Neuro Oncol 2016; 18: 132-41. doi: 10.1093/neuonc/nov147
- Cao M, Suo S, Han X, Jin K, Sun Y, Wang Y, et al. Application of a simplified method for estimating perfusion derived from diffusion-weighted MR imaging in glioma grading. Front Aging Neurosci 2018; 9: 432. doi: 10.3389/fnagi.2017.00432
- Conklin J, Heyn C, Roux M, Cerny M, Wintermark M, Federau C. A simplified model for intravoxel incoherent motion perfusion imaging of the brain. AJNR Am J Neuroradiol 2016; 37: 2251-7. doi: 10.3174/ajnr.A4929
- Shukla-Dave A, Lee NY, Jansen JFA, Thaler HT, Stambuk HE, Fury MG, et al. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. Int J Radiat Oncol Biol Phys 2012; 82: 1837-44. doi: 10.1016/j.ijrobp.2011.03.006
- Thoeny HC, de Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237: 492-9. doi: 10.1148/radiol.2372041638
- Teruel JR, Goa PE, Sjøbakk TE, Østlie A, Fjøsne HE, Bathen TF. A simplified approach to measure the effect of the microvasculature in diffusion-weighted MR imaging applied to breast tumors: preliminary results. Radiology 2016; 281: 373-81. doi: 10.1148/radiol.2016151630
- Federau C, Maeder P, O’Brien K, Browaeys P, Meuli R, Hagmann P. Quantitative measurement of brain perfusion with intravoxel incoherent motion MR imaging. Radiology 2012; 265: 874-81. doi: 10.1148/radiol.12120584
- Suo S, Cao M, Zhu W, Li L, Li J, Shen F, et al. Stroke assessment with intravoxel incoherent motion diffusion-weighted MRI. NMR Biomed 2016, 29: 320-8. doi: 10.1002/nbm.3467
- Zhang Q, Wang Y-X, Ma HT, Yuan J. Cramér-Rao bound for intravoxel incoherent motion diffusion weighted imaging fitting. Conf Proc IEEE Eng Med Biol Soc 2013; 2013: 511-4. doi: 10.1109/EMBC.2013.6609549
- While PT, Teruel JR, Vidić I, Bathen TF, Goa PE. Relative enhanced diffusivity: noise sensitivity, protocol optimization, and the relation to intravoxel incoherent motion. MAGMA 2018; 31: 425-38. doi: 10.1007/s10334-017-0660-x
- Wu W-C, Chen Y-F, Tseng H-M, Yang S-C, My P-CJER. Caveat of measuring perfusion indexes using intravoxel incoherent motion magnetic resonance imaging in the human brain. Eur Radiol 2015; 25: 2485-92. doi: 10.1007/s00330-015-3655-x
- Chung WJ, Kim HS, Kim N, Choi CG, Kim SJ. Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging. Radiology 2013; 269: 561-8. doi: 10.1148/radiol.13130016
- Han X, Suo S, Sun Y, Zu J, Qu J, Zhou Y, et al. Apparent diffusion coefficient measurement in glioma: Influence of region-of-interest determination methods on apparent diffusion coefficient values, interobserver variability, time efficiency, and diagnostic ability. J Magn Reson Imaging 2017; 45: 722-30. doi: 10.1002/jmri.25405
- Park JE, Kim HS, Park KJ, Kim SJ, Kim JH, Smith SA. Pre-and posttreatment glioma: comparison of amide proton transfer imaging with MR spectroscopy for biomarkers of tumor proliferation. Radiology 2015; 278: 514-23. doi: 10.1148/radiol.2015142979
- Bisdas S, Braun C, Skardelly M, Schittenhelm J, Teo TH, Thng CH, et al. Correlative assessment of tumor microcirculation using contrast-enhanced perfusion MRI and intravoxel incoherent motion diffusion-weighted MRI: is there a link between them? NMR Biomed 2014; 27: 1184-91. doi: 10.1002/nbm.3172
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
- Zou T, Yu H, Jiang C, Wang X, Jiang S, Rui Q, et al. Differentiating the histologic grades of gliomas preoperatively using amide proton transfer-weighted (APTW) and intravoxel incoherent motion MRI. NMR Biomed 2018; 31. doi: 10.1002/nbm.3850
- Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999; 9: 53-60. doi: 10.1002/(sici)1522-2586(199901)9:1<;53::Aid-jmri7>3.0.Co;2-2
- Matsumoto Y, Kuroda M, Matsuya R, Kato H, Shibuya K, Oita M, et al. In vitro experimental study of the relationship between the apparent diffusion coefficient and changes in cellularity and cell morphology. Oncol Rep 2009; 22: 641-8. doi: 10.3892/or_00000484
- Chen L, Liu M, Bao J, Xia Y, Zhang J, Zhang L, et al. The Correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis. PLoS One 2013; 8: e79008. doi: 10.1371/journal.pone.0079008
- Provenzale JM, York G, Moya MG, Parks L, Choma M, Kealey S, et al. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. AJR Am J Roentgenol 2006; 187: 1036-42. doi: 10.2214/AJR.04.0676
- Mills SJ, Patankar TA, Haroon HA, Balériaux D, Swindell R, Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006; 27: 853-8.
- Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010; 75: 1560-6. doi: 10.1212/WNL.0b013e3181f96282
- Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014; 16: 81-91. doi: 10.1212/WNL.0b013e3181f96282
- Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015; 372: 2499-508. doi: 10.1056/NEJMoa1407279
- Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013; 13: 345. doi: 10.1007/s11910-013-0345-4
- Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-5. doi: 10.1126/science.1170944
- Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, Deimling Av, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 2015; 5: 16238. doi: 10.1038/srep16238
- Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, et al. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. J Neurooncol 2017; 134: 177-88. doi: 10.1007/s11060-017-2506-9
- Brendle C, Hempel JM, Schittenhelm J, Skardelly M, Tabatabai G, Bender B, et al. Glioma grading and determination of IDH mutation status and ATRX loss by DCE and ASL perfusion. Clin Neuroradiol 2018; 28: 421-8. doi: 10.1007/s00062-017-0590-z
- Cui D, Ren J, Shi J, Feng L, Wang K, Zeng T, et al. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling. Int J Biochem Cell Biol 2016; 73: 72-81. doi: 10.1016/j.biocel.2016.02.007
- Reis M, Czupalla CJ, Ziegler N, Devraj K, Zinke J, Seidel S, et al. Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med 2012; 209: 161127. doi: 10.1084/jem.20111580
- Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484-8. doi: 10.1038/nature10898
- Villanueva-Meyer JE, Wood MD, Choi BS, Mabray MC, Butowski NA, Tihan T, et al. MRI Features and IDH mutational status of grade II diffuse gliomas: impact on diagnosis and prognosis. AJR Am J Roentgenol 2018; 210: 621-8. doi: 10.2214/AJR.17.18457